Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$140.00 | -$0.16 | Beat |
| May 5, 2026 | -$140.00 | -$0.14 | Beat |
| Mar 19, 2026 | -$5.50 | -$0.08 | Beat |
| Nov 7, 2025 | – | -$0.07 | |
| Aug 8, 2025 | – | -$0.19 | |
| May 14, 2025 | – | -$0.05 |